1. Hodel EM, Kay K, Hastings IM. 2016 Incorporating stage-specific drug action into pharmacological modeling of antimalarial drug treatment.
Antimicrob Agents Chemother 2016;60(5):2747-2756
https://doi.org/10.1128/AAC.01172-15
3. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening.
Nat Rev Drug Discov 2004;3(6):509-520
https://doi.org/10.1038/nrd1416
4. Wengelnik K, Vidal V, Ancelin ML, Cathiard AM, Morgat JL, et al. A class of potent antimalarials and their specific accumulation in infected erythrocytes.
Science 2002;295(5558):1311-1314
https://doi.org/10.1126/science.1067236
5. Owolabi ATY, Reece SE, Schneider P. Daily rhythms of both host and parasite affect antimalarial drug efficacy.
Evol Med Public Health 2021;9(1):208-219
https://doi.org/10.1093/emph/eoab013
6. Wilson DW, Langer C, Goodman CD, McFadden GI, Beeson JG. Defining the timing of action of antimalarial drugs against
Plasmodium falciparum.
Antimicrob Agents Chemother 2013;57(3):1455-1467
https://doi.org/10.1128/AAC.01881-12
7. Kim HS, Nagai Y, Ono K, Begum K, Wataya Y, et al. Synthesis and antimalarial activity of novel medium-sized 1,2,4,5-tetraoxacycloalkanes.
J Med Chem 2001;44(14):2357-2361
https://doi.org/10.1021/jm010026g
8. Sato A, Hiramoto A, Morita M, Matsumoto M, Komich Y, et al. Antimalarial activity of endoperoxide compound 6-(1,2,6,7-tetraoxaspiro [7.11] nonadec-4-yl) hexan-1-ol.
Parasitol Int 2011;60(3):270-273
https://doi.org/10.1016/j.parint.2011.04.001
9. Morita M, Koyama T, Sanai H, Sato A, Hiramoto A. Stage specific activity of synthetic antimalarial endoperoxides, N-89 and N-251, against
Plasmodium falciparum.
Parasitol Int 2015;64(1):113-117
https://doi.org/10.1016/j.parint.2014.10.007
10. Leelaviwat N, Mekraksakit P, Cross KM, Landis DM, McLain M, et al. Melatonin: Translation of ongoing studies into possible therapeutic applications outside sleep disorders.
Clin Ther 2022;44(5):783-812
https://doi.org/10.1016/j.clinthera.2022.03.008
11. Hotta CT, Gazarini ML, Beraldo FH, Varotti FP, Lopes C, et al. Calcium-dependent modulation by melatonin of the circadian rhythm in malarial parasites.
Nature Cell Biol 2000;2(7):466-468
https://doi.org/10.1038/35017112
12. Mallaupoma LRC, Dias BKM, Singh MK, Honorio RI, Nakabashi M, et al. Decoding the role of melatonin structure on
Plasmodium falciparum human malaria parasites synchronization using 2-sulfenylindoles derivatives.
Biomolecules 2022;12(5):638
https://doi.org/10.3390/biom12050638
13. Peters W. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann Trop Med Parasitol 1975;69(2):155-171.
14. Smith LM, Motta FC, Chopra G, Moch JK, Nerem RR, et al. An intrinsic oscillator drives the blood stage cycle of the malaria parasite
Plasmodium falciparum.
Science 2020;368(6492):754-759
https://doi.org/10.1126/science.aba4357
15. Beraldo FH, Almeida FM, da Silva AM, Garcia CR. Cyclic AMP and calcium interplay as second messengers in melatonin-dependent regulation of
Plasmodium falciparum cell cycle.
J Cell Biol 2005;170(4):551-557
https://doi.org/10.1083/jcb.200505117
16. Singh MK, Dias BKM, Garcia CRS. Role of melatonin in the synchronization of asexual forms in the parasite
Plasmodium falciparum.
Biomolecules 2020;10(9):1243
https://doi.org/10.3390/biom10091243
19. Pereira PHS, Garcia CRS. Melatonin action in
Plasmodium infection: Searching for molecules that modulate the asexual cycle as a strategy to impair the parasite cycle.
J Pineal Res 2021;70(1):e12700
https://doi.org/10.1111/jpi.12700
20. Bagnaresi P, Alves E, Borges da Silva H, Epiphanio S, et al. Unlike the synchronous
Plasmodium falciparum and
P. chabaudi infection, the
P. berghei and
P. yoelii asynchronous infections are not affected by melatonin.
Int J Gen Med 2009;2:47-55
https://doi.org/10.2147/ijgm.s3699
21. Shuto S, Minakawa N, Niizuma S, Kim HS, Wataya Y, et al. New neplanocin analogs 12. An alternative synthesis of (6′R)-6′-C-methylneplanocin A (RMNPA), a novel potent anti-malarial agent.
J Med Chem 2002;45(3):748-751
https://doi.org/10.1021/jm010374i
22. Kim HS, Shibata Y, Wataya Y, Tsuchiya K, Masuyama A, et al. Synthesis and antimalarial activity of cyclic peroxides, 1,2,4,5,7-pentoxocanes and 1,2,4,5-tetroxanes.
J Med Chem 1999;42(14):2604-2609
https://doi.org/10.1021/jm990014j
23. Tsuchiya K, Hamada Y, Masuyama A, Nojima M, McCullough KJ, et al. Synthesis, crystal structure and anti-malarial activity of novel spiro-1,2,4,5-tetraoxacycloalkanes.
Tetrahedron Lett 1999;40(21):4077-4080
https://doi.org/10.1016/S0040-4039(99)00653-X
24. Miyaoka H, Shimomura M, Kimura H, Yamada Y, Kim HS, et al. Antimalarial activity of kalihinol A and new relative diterpenoids from the okinawan sponge,
Acanthella sp.
Tetrahedron 1998;54(44):13467-13474
https://doi.org/10.1016/S0040-4020(98)00818-7
25. Aly NS, Hiramoto A, Sanai H, Hiraoka O, Hiramoto K, et al. Proteome analysis of new antimalarial endoperoxide against
Plasmodium falciparum.
Parasitol Res 2007;100(5):1119-1124
https://doi.org/10.1007/s00436-007-0460-8
26. Morita M, Sanai H, Hiramoto A, Sato A, Hiraoka O, et al.
Plasmodium falciparum endoplasmic reticulum-resident calcium binding protein is a possible target of synthetic antimalarial endoperoxides, N-89 and N-251.
J Proteome Res 2012;11(12):5704-5711
https://doi.org/10.1021/pr3005315